跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection multidose vial - TGA Drug Approval Details
Approvals
/
TGA
/
COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection multidose vial
Approved
STANDARD
COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection multidose vial
Pfizer Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
Dec 9, 2025
Approval ID
da0cba27ccaa26fd
Company
Pfizer Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
da0cba27ccaa26fd
Product Name
COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection multidose vial
Artg Id
506527
Artg Name
COMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection multidose vial
Sponsor
Pfizer Australia Pty Ltd
Company Detail Path
/organization/pfizer-australia-pty-ltd
Artg Date
2025-10-01
Registration Type
Medicine
Therapeutic Good Type
Medicines
Licence Status
A
Licence Category
RE
Product Information
https://medical-cdn.nocode.com/drug_tga/7828c8e436a60b0dd373553bdb355954.pdf
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
Dec 9, 2025
Approval ID
da0cba27ccaa26fd
Type
Standard
Back to TGA Approvals